PILOT STUDY FOR IDENTIFYING URINARY PROSTATE CANCER BIOMARKERS

鉴定尿路前列腺癌生物标志物的试点研究

• 批准号: 7957018
• 负责人: ALVIN Y LIU
• 金额: $ 6.5万
• 依托单位: BATTELLE PACIFIC NORTHWEST LABORATORIES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7957018
• 关键词: Biological Markers; Biology; Biopsy; Computer Retrieval of Information on Scientific Projects Database; Development; Funding; Genomics; Grant; Institution; Investigation; Malignant Neoplasms; Malignant neoplasm of prostate; Pilot Projects; Proteins; Proteomics; Research; Research Personnel; Resources; Sampling; Screening for cancer; Source; Technology; Testing; Time; United States National Institutes of Health; Urine; cancer cell; multiple reaction monitoring; serum PSA; urinary

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Urinary prostate cancer protein biomarkers are important for early cancer detection. A urine test at the early time point can significantly reduce the number of unnecessary biopsies done as a result of elevated serum PSA. The application of genomics to cancer cells has allowed the identification of a number of candidate biomarkers for further investigations. This pilot study will utilize the advanced targeted proteomics technology using multiple reaction monitoring (MRM) under the Research Center for testing the discriminatory power of identified cancer proteins in urine samples. The application is also anticipated to drive further development and optimization of the targeted MRM technology.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 尿前列腺癌蛋白生物标记物对癌症的早期检测具有重要意义。在早期进行尿检可以显著减少由于血清PSA升高而进行的不必要的活检次数。基因组学在癌细胞上的应用使人们能够确定一些候选生物标记物，以便进行进一步的研究。这项初步研究将利用先进的靶向蛋白质组学技术，使用研究中心下的多反应监测(MRM)来测试尿样中已识别的癌症蛋白的区分能力。预计该应用还将推动目标MRM技术的进一步开发和优化。